Santhera Pharmaceuticals Holding AG (SWX: SANN)
Health Care · Biotechnology · CH
CHF14.56
+1.96% today · +37.8% 1Y
Santhera Pharmaceuticals Holding AG (SWX: SANN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $263.01M and employs 78 people.
Over the last twelve months the share price has gained 37.8%, trading between 9.38 and 18.84.
Tweenvest scores Santhera Pharmaceuticals Holding AG across four factors: quality 36/100, value 79/100. Its strongest factor is value.
SANN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $263.01M
- Revenue (TTM)
- $125.62M
- P/E
- —
- EPS
- -2.32
- Dividend yield
- —
- Beta (5Y)
- -0.39
- 52-week high
- CHF18.84
- 52-week low
- CHF9.38
- Avg volume (3M)
- —
- Shares outstanding
- 15.30M
- Employees
- 78
- Next earnings
- —
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
- ISIN
- CH1276028821
- Founded
- 2004
- Listed since
- Nov 3, 2006
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mabpharm LimitedSEHK: 2181 | $265.39M | HK$0.51 | +3.06% |
| BridgeBio Oncology Therapeutics, Inc.NasdaqGM: BBOT | $265.38M | $3.31 | -14.91% |
| Lexeo Therapeutics, Inc.NasdaqGM: LXEO | $265.00M | $3.23 | -8.50% |
| Inventage Lab, Inc.KOSDAQ: A389470 | $263.31M | ₩26,600.00 | -6.01% |
| Obigen Pharma Inc.TPEX: 7876 | $262.25M | NT$78.20 | +21.81% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $262.04M | $19.58 | +1.82% |
| Fate Therapeutics, Inc.NasdaqGM: FATE | $261.21M | $2.11 | -3.21% |
| VISEN PharmaceuticalsSEHK: 2561 | $259.19M | HK$18.61 | +0.59% |
Figures last refreshed Oct 11, 2026.